Visoluten

Bioregulator / Visual system

Supports retina/eye tissues functional activity and tissue-specific restoration

Reading this compound Reference only

Information below is educational. Dosing, mechanisms and status fields are compiled from the source list at the bottom of this page — always verify against a licensed clinician before use.

Reference-only summary of publicly discussed or source-listed patterns. Not medical advice and not a personal recommendation.

Mechanism & Use

Compound type: Peptide bioregulator
Primary mechanism: Organ-specific peptide fractions; tissue-selective gene-expression/protein synthesis support
Primary market use: Bioregulator / Visual system
Bioregulator family: Cytomax / natural oral bioregulator
Tissue / organ target: Retina/eye tissues
Cytomax A-code: A-11
Cytogen equivalent: Vilon

Pharmacology

Oral bioavailability: Route-dependent / verify
Half-life: Plasma t1/2 not central; oral protocol aftereffect 6–12 months
Route tags: Oral; Lingual
Evidence level: Bioregulator guide / practitioner-market protocol signal
Clinical status: Supplement/research bioregulator; jurisdiction-dependent
Value-for-money score: 8 / 10
Durability / after-effect: Aftereffect/durability window: 6–12 months reported for Cytomax oral cycles.

Reported protocol signal

Common reported Cytomax oral protocol: 1–2 capsules, 1–2×/day with food for 30 days; alternate schema 10 mg twice daily for 10–20 days, repeated 3–4×/year with 2–3 month rest.

For orientation only. See disclaimer — always consult a licensed clinician before use.

Stackability

Connect to Bioregulator_Map and Protocol_Templates sheets; do not treat stacks as standalone compounds.

Notes

Cytomax/Cytogen/lingual peptide bioregulator product; organ-specific peptide complex